ERCC2

Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer

M. G. He, Zheng, K., Tan, D., Wang, Z. X., He, M. G., Zheng, K., Tan, D., Wang, Z. X., He, M. G., Zheng, K., Tan, D., and Wang, Z. X., “Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer”, vol. 15, p. -, 2016.

We conducted a study to investigate the association between ERCC1 (rs3212986) and ERCC2 (rs13181) gene polymorphisms and the risk of pancreatic cancer in a Chinese population. A total of 217 pancreatic cancer patients and 244 control subjects were recruited from the Nuclear Industry 215 Hospital of Shaanxi Province between February 2013 and December 2014. Genomic DNA was extracted from peripheral blood samples using a TIANamp Blood DNA Kit (Tiangen, Beijing, China) according to the manufacturer’s instructions.

Role of ERCC2 and ERCC3 gene polymorphisms in the development of osteosarcoma

X. Ma, Zhang, Y., Sun, T. S., Yao, J. H., Ma, X., Zhang, Y., Sun, T. S., Yao, J. H., Ma, X., Zhang, Y., Sun, T. S., and Yao, J. H., “Role of ERCC2 and ERCC3 gene polymorphisms in the development of osteosarcoma”, vol. 15, p. -, 2016.

We conducted a case-control study to investigate the role of common SNPs in ERCC2 (rs13181 and rs1799793) and ERCC3 (rs4150441 and rs4150506) in the development of osteosarcoma. A 1:2 matched case-control study was conducted. Between January 2012 and December 2013, 141 patients with pathologically diagnosed osteosarcoma and 282 controls were recruited in our study. Genotyping of ERCC2 rs13181 and rs1799793 as well as ERCC3 rs4150441 and rs4150506 were performed using polymerase chain reaction coupled with restriction fragment length polymorphism.

Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis

T. L. Jia, Wu, H. J., Wang, H. B., Ma, W. B., and Xing, B., “Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis”, vol. 14, pp. 12577-12584, 2015.

Several studies have focused on the association between the ERCC2 rs13181 polymorphism and glioma risk, but the results were inconclusive. We aimed to conduct a meta-analysis to investigate the role of ERCC2 rs13181 on the risk of glioma. We searched and collated the relevant studies in both Chinese and English through the PubMed, Web of Science, Cochrane Library, and EMBASE databases published through June 1, 2014. A total of 11 studies for ERCC2 rs13181 were selected; these included 3456 glioma cases and 4957 controls.

Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients

G. Zhong, Li, H. K., Shan, T., and Zhang, N., “Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients”, vol. 14, pp. 17228-17234, 2015.

We investigate whether three common polymorphisms in ERCC1 and ERCC2 are predictor factors for the chemotherapy response, as well as the clinic outcome of patients with gastric cancer. Between May 2011 and May 2013, 263 patients with gastric cancer who were newly diagnosed by histopathology were enrolled in our study. Genotyping of the ERCC1 rs11615 and rs3212986, and ERCC2 rs1799793 polymorphisms were conducted by the polymerase chain reaction-restriction fragment length polymorphism assay.

Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer

W. H. Yu, Wang, Y. X., Guo, J. Q., Wang, Y. L., Zheng, J. S., and Zhu, K. X., “Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer”, vol. 14, pp. 17529-17535, 2015.

We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer. A total of 346 patients with gastric cancer were recruited between May 2009 and May 2012. Single nucleotide polymorphism genotyping was performed using the Sequenom MassARRAY platform. The GA+AA genotype of ERCC2 rs1799793 showed significant and favorable response to chemotherapy than the wide-type GG genotype in multivariate analysis (OR = 1.78, 95%CI = 1.13-2.81).

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Z. H. Cao, Yin, H. P., Jiang, N., and Yu, B., “Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma”, vol. 14, pp. 10145-10151, 2015.

We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. We identified 186 patients with osteosarcoma diagnosed between April 2009 and April 2011 who were eligible for inclusion in our study. Genotyping of ERCC1 rs11615, rs3212986, and rs2298881; and ERCC2 rs1799793 and rs13181 was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.

Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma

Q. Zhang, Lv, L. Y., Li, B. J., Zhang, J., and Wei, F., “Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma”, vol. 14, pp. 11235-11241, 2015.

We assessed the role of single nucleotide polymorphisms (SNPs) in ERCC1 and ERCC2 genes in the clinical outcomes for osteosarcoma patients receiving cisplatin-based treatment. A perspective study was conducted on 260 patients with osteosarcoma during 2010 and 2011. A polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was used to assess the ERCC1 rs11615 and rs3212986, and the ERCC2 rs1799793 and rs13181 gene polymorphisms.

Subscribe to ERCC2